Galderma   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lausanne Switzerland (1981)
Status: Acquired by Nestle (2014)

Organization Overview

First Clinical Trial
2000
NCT00473343
First Marketed Drug
1984
prednisone (meticorten)
First NDA Approval
1996
adapalene (differin)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Galderma | Galderma Brasil Lltda | Galderma Brasil Ltda. | Galderma Canada | Galderma investigational center | Galderma Laboratories | Galderma Laboratories, LP | Galderma Laboratories, L.P. | Galderma Laboratorium GmbH | GALDERMA LABS | GALDERMA LABS LP | GALDERMA R AND D | Galderma R&D | Galderma R&D, Inc | Galderma R&D, Inc. | Galderma R&D, LLC

Active Ingredients

Marketed Drugs (15)

Key: Galderma (14) Acquired (1)

adapalene (differin) (1996 NDA)

benzoyl peroxide (clearasil) (2015)

brimonidine (alphagan) (2013)

calcitriol (rocaltrol) (2009)

clobetasol (dermovate) (2004)

doxycycline (vibramycin) (2001)

fluocinolone acetonide (synalar) (1990)

hydroquinone (2002)

ivermectin (stromectol) (2014)

mequinol (Solage) (NDA)

methyl aminolevulinate (metvixia) (2004)

metronidazole (flagyl) (1988)

prednisone (meticorten) (1984)

tretinoin (Retin-A) (NDA)

trifarotene (Aklief) (2019 NDA)

Drugs in Phase 4 Trials (36)

Key: Galderma (31) Acquired (5)

abobotulinumtoxinA (Dysport) (6 trials)

adapalene (differin) (40 trials)

aloe vera (1 trial)

aminolevulinic acid (levulan) (1 trial)

Amorolfine (loceryl) (3 trials)

azelaic acid (azelex) (5 trials)

benzocaine (Orajel) (1 trial)

benzoyl peroxide (clearasil) (23 trials)

betamethasone (celestone) (2 trials)

brimonidine (alphagan) (16 trials)

calcipotriene (dovonex) (2 trials)

calcitriol (rocaltrol) (10 trials)

ciclopirox (loprox) (1 trial)

clindamycin (cleocin) (1 trial)

clobetasol (dermovate) (11 trials)

doxycycline (vibramycin) (14 trials)

fluocinolone acetonide (synalar) (4 trials)

glycolic acid (1 trial)

hyaluronic acid (6 trials)

hydroquinone (4 trials)

ivermectin (stromectol) (8 trials)

lidocaine (xylocaine) (2 trials)

metronidazole (flagyl) (6 trials)

niacinamide (10 trials)

onabotulinumtoxinA (Botox) (8 trials)

palmityl alcohol (5 trials)

propylene glycol (5 trials)

rimabotulinumtoxinB (Myobloc) (8 trials)

salicylic acid (1 trial)

sodium monododecyl sulfate (5 trials)

tazarotene (tazorac) (2 trials)

tetracaine (pontocaine) (2 trials)

tretinoin (Retin-A) (7 trials)

trifarotene (Aklief) (9 trials)

trifonazole (1 trial)

urea (2 trials)

Drugs in Phase 3 Trials (6)

hydrogen peroxide (4 trials)

isotretinoin (Accutane) (1 trial)

ketoconazole (nizoral) (1 trial)

methyl aminolevulinate (metvixia) (10 trials)

nemolizumab (16 trials)

tetracycline (tetrex) (1 trial)

Drugs in Phase 2 Trials (7)

Key: Galderma (5) Acquired (2)

auriclosene (1 trial)

cd2475/101 (1 trial)

hypromelloses (1 trial)

naphazoline (visine) (1 trial)

np000888 (1 trial)

resiquimod (3 trials)

sertaconazole (ertaczo) (1 trial)

Drugs in Phase 1 Trials (1)

polylactic acid (2 trials)

Drugs in Other Trials (3)

cetyl alcohol (1 trial)

minoxidil (loniten) (2 trials)

octocrylene (1 trial)

Indications

Approved Indications


 

Acne Vulgaris

Hyperpigmentation

Leukemia, Promyelocytic, Acute

Melanosis

Pigmentation Disorders

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 4)

Atrophy (Phase 4)

Blepharitis (Phase 2)

Congenital Abnormalities (Phase 3)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Dermatitis, Seborrheic (Phase 3)

Eczema (Phase 3)

Erythema (Phase 4)

Facies (Phase 4)

Flushing (Phase 2)

Foot Dermatoses (Phase 4)

Hypersensitivity (Phase 4)

Inflammation (Phase 2)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Lentigo (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanosis (Phase 4)

Neurodermatitis (Phase 3)

Onychomycosis (Phase 4)

Prurigo (Phase 3)

Psoriasis (Phase 4)

Purpura (Phase 2)

Rosacea (Phase 4)

Skin Diseases (Phase 4)

Skin Manifestations (Phase 4)

Skin Ulcer (Phase 3)

Striae Distensae (Phase 1)

Vascular Malformations (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 190
  • # of Trial APIs: 53